In: Cardiovascular Revascularization Medicine, 2019, vol. 20, no. 7, p. 577–582
Background: The advent of bioresorbable vascular scaffolds (BVS) was considered as a potential improvement in percutaneous coronary intervention (PCI) after the groundbreaking development of drug eluting stents (DES). However, the clinical performance, long-term safety and efficacy of BVS in complex coronary lesions remain uncertain. COMPARE ABSORB, a multicenter, single blind, prospective ...
|
In: European Heart Journal, 2016, vol. 37, no. 26, p. 2040–2049
Background Peri-stent coronary evaginations may disturb flow and have been proposed as possible risk factor for late stent thrombosis. We describe incidence, predictors, and possible mechanisms of coronary evaginations 12 months after implantation of bioresorbable vascular scaffolds (BVS).Methods and results One hundred and two BVS implanted in 90 patients...
|
In: Journal of the American College of Cardiology, 2016, vol. 67, no. 8, p. 921–931
Background Recent reports suggest an elevated incidence of bioresorbable vascular scaffold (BVS) thrombosis (scaffold thrombosis [ScT]).Objectives This study investigated occurrence rates, clinical and angiographic characteristics, and possible mechanisms of ScT in all-comer patients undergoing BVS implantation at 2 German and 2 Swiss hospitals.Methods A total of 1,305 consecutive patients...
|
In: Circulation: Cardiovascular Interventions, 2015, vol. 8, no. 10, p. e002518
Background—Everolimus-eluting bioresorbable vascular scaffolds have been developed to improve late outcomes after coronary interventions. However, recent registries raised concerns regarding an increased incidence of scaffold thrombosis (ScT). The mechanism of ScT remains unknown.Methods and Results—The present study investigated angiographic and optical...
|